Hot Biotech Movers: Achillion Pharmaceuticals (NASDAQ:ACHN), Celgene Corporation (NASDAQ:CELG), Gilead Sciences Inc. (NASDAQ:GILD), MannKind Corp. (NASDAQ:MNKD), Genetic Technologies Limited (NASDAQ:GENE)

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) announced the pricing of an underwritten public offering of 12 million shares of its common stock at a price to the public of $10.25 per share. On Thursday shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) closed at $11.09. Company’s EPS growth for next 5 years is recorded as 17.58%.

Celgene Corporation (NASDAQ:CELG) announced that its oncology drug, Abraxane, has received a positive recommendation from the Scottish Medicines Consortium (SMC) within the National Health Service (NHS) Scotland. Celgene Corporation (NASDAQ:CELG) in last trading activity moved down -2.25% to close at $115.72. Company weekly performance is -3.58% while its quarterly performance stands at 7.30%. Celgene Corporation (NASDAQ:CELG) is -7.13% away from its 52 week high.

On 3 February, Gilead Sciences, Inc. (NASDAQ:GILD) announced that the company‚Äôs Board of Directors has authorized a dividend program under which the company intends to pay quarterly dividends of $0.43 per share, beginning in the second quarter of 2015, subject to quarterly declarations by the Board of Directors. On last trading day Gilead Sciences Inc. (NASDAQ:GILD) moved up 0.82% to close at $100.80. Its volatility for the week is 2.46% while volatility for the month is 3.05%. GILD’s sales growth for past 5 years was 28.80% and its EPS growth for past 5 years was 39.10%. Gilead Sciences Inc. (NASDAQ:GILD) monthly performance is 3.69%.

On 3 February, Sanofi and Valencia-based MannKind Corp. (NASDAQ:MNKD) announced Afrezza (insulin human) Inhalation Powder, the only inhaled insulin, is now available by prescription in U.S. retail pharmacies nationwide. MannKind Corp. (NASDAQ:MNKD) has 0.70% insider ownership while its institutional ownership stands at 23.30%. In last trading activity company’s stock closed at $6.98.

On last trading day Genetic Technologies Limited (NASDAQ:GENE) moved up 36.44% to close at $6.14. Its volatility for the week is 28.06% while volatility for the month is 34.77%. GENE’s sales growth for past 5 years was -16.80% and its EPS growth for past 5 years was 3.30%. Genetic Technologies Limited (NASDAQ:GENE) monthly performance is 223.16%.

Leave a Reply

Your email address will not be published. Required fields are marked *